Martínez-Pérez Diana Cristina, Gómez-Wolff Luis Rodolfo, Ossa-Gómez Carlos Andrés, Hernández-Herrera Gilma Norela, Rivas-Bedoya Yamile, García-García Héctor Iván
Magíster en Epidemiología Clínica, Universidad de Antioquia, Medellín, Colombia.
Especialista en Oncología Clínica, Instituto de Cancerología Las Américas, Medellín, Colombia.
Rev Colomb Obstet Ginecol. 2020 Jun;71(2):87-102. doi: 10.18597/rcog.3410.
To determine the association between delayed diagnosis and advanced clinical stage breast cancer, and to explore the factors that influence this delay.
Cross-sectional study of women over 18 years of age with breast cancer who attended 4 oncology centers in Medellín, Colombia, in 2017. The "Breast Cancer Delay Questionnaire" which includes sociodemographic and clinical variables as well as time intervals was used. Crude and adjusted odds ratio (OR) were estimated, using advanced clinical stage as outcome and delayed diagnosis as exposure.
42 patients were included. The median time interval between the identification of the problem and the diagnostic biopsy was 104.5 days; between the identification of the problem and the first medical visit, 20 days; and between the first visit and the diagnostic biopsy, 53 days. Of all the cases, 52.1 % were diagnosed at an advanced stage. An association was found between delayed diagnosis and advanced clinical stage (OR = 2.15 95 % CI 1.21-3.79). Age above 40 was found to be a protective factor against having an advanced-stage lesion (OR = 0.35; 95 % CI: 0.14-0.83). Delayed diagnosis was associated with affiliation to the government subsidized health system (OR = 9.67; 95 % CI 2.76- 33.9) and age over 40 years (OR = 2.75; 95 % CI1.16-6.53).
Patient education is required in order to ensure adherence to early screening programs or timely consultation whenever a sign or symptom is identified, thus allowing diagnosis at an early stage of the disease. Moreover, prospective studies are needed in order to identify factors associated with delays in treatment after the diagnosis of breast cancer, and to assess interventions designed to reduce delays in the care of this form of cancer.
确定延迟诊断与晚期乳腺癌临床分期之间的关联,并探讨影响这种延迟的因素。
对2017年在哥伦比亚麦德林4家肿瘤中心就诊的18岁以上乳腺癌女性进行横断面研究。使用了“乳腺癌延迟问卷”,其中包括社会人口统计学和临床变量以及时间间隔。以晚期临床分期为结果,延迟诊断为暴露因素,估计粗比值比(OR)和调整后的比值比。
纳入42例患者。从发现问题到诊断性活检的中位时间间隔为104.5天;从发现问题到首次就诊为20天;从首次就诊到诊断性活检为53天。所有病例中,52.1%在晚期被诊断。发现延迟诊断与晚期临床分期之间存在关联(OR = 2.15,95%CI 1.21 - 3.79)。40岁以上年龄是预防晚期病变的保护因素(OR = 0.35;95%CI:0.14 - 0.83)。延迟诊断与加入政府补贴医疗系统有关(OR = 9.67;95%CI 2.76 - 33.9)以及40岁以上年龄(OR = 2.75;95%CI 1.16 - 6.53)。
需要对患者进行教育,以确保他们坚持早期筛查计划,或在发现任何体征或症状时及时咨询,从而在疾病早期进行诊断。此外,需要进行前瞻性研究,以确定与乳腺癌诊断后治疗延迟相关的因素,并评估旨在减少这种癌症护理延迟的干预措施。